Aerovate Therapeutics (AVTE) has bullish potential due to its recent merger with Jade Biosciences, which brought a 24% pre-market stock surge and $300M in committed investment support. The strategic alternatives review and financial backing could drive shareholder value, with the stock trading at $1.66 as of July 2024. However, its halted clinical trials and missed EPS estimates (-$0.86 vs. -$0.83) highlight risks.